Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
295 Leser
Artikel bewerten:
(1)

ACDM Honors PHASTAR with Award for Innovation in the Management of Clinical Trial Data

DURHAM, NC and LONDON, UK / ACCESSWIRE / September 22, 2021 / PHASTAR, a global specialist biometrics contract research organization (CRO) offering industry leading data management, data science, statistical consulting and clinical trial reporting services, was announced as a joint winner of the 2021 Innovation in the Management of Clinical Data Award by the Association for Clinical Data Management (ACDM).

The award was in recognition of the work done by PHASTAR data scientists and data managers to develop a novel AI and rule-based approach for the production of auto-generated queries used to identify potential data issues and inconsistencies in clinical trial data. The PHASTAR team integrated the role of the human expert with intelligent process automation through a targeted approach. They are able to discover hotspots of data quality issues on studies through the application of AI (NLP) approaches to the meta data, identifying problematic forms and variables and are now building labelled data sets to which machine learning methods may be applied.

"It is truly a honor to be recognized by our industry peers for the outstanding contributions PHASTAR data science and data management teams have made to assure more accurate outcomes in clinical trials," said Andrew MacGarvey, Chief Executive Officer, PHASTAR. "Data quality is an important pillar in the successful collection of clinical data. By creating innovative approaches, the application of advanced technologies like AI and Machine Learning will continue to impact the success of drug discovery and development."

The Association for Clinical Data Management (ACDM) represents professionals working in the management of clinical data. Founded over 30 years ago, they have been at the forefront of changes in all aspects of the management of clinical data in clinical trials and support their members through training, conferences, discussions and information provision. ACDM represents and supports professionals involved with managing, capturing, handling and designing methods to collect clinical data from within the pharmaceutical, biotechnology and academic research fields.

About PHASTAR

PHASTAR is a global specialist biometrics contract research organization offering industry leading data management, data science, statistical consulting, and clinical trial reporting services by providing expert consultants and managing and delivering in-house projects, FSP style arrangements and preferred partnerships. PHASTAR currently has over staff across 14 offices (United States, United Kingdom, Australia, Germany, Kenya, Japan, India and China) with plans to open additional locations in the future to serve prospective and existing clients. PHASTAR's number one priority is to ensure that the work produced is of the highest quality. Every project PHASTAR undertakes utilizes unique internal processes which are designed to ensure optimal quality.

All PHASTAR's data management, data science statistical and programming, staff are trained in the "PHASTAR Discipline" - an in-house approach to data analysis and collection. This comprises a set of common sense (but commonly ignored) principles that, if followed, guarantee error free outcomes. The "PHASTAR Discipline" also includes a series of intranet-based checklists highlighting potential pitfalls and points-to-consider when conducting clinical trials, enabling over 4,000 years of combined technical knowledge to be shared across the company.

For further information on PHASTAR contact tellmemore@phastar.com.

U.S. Media Contact

Dawn Fontaine
Ripple Effect Communications
617-536-8887
dawn@rippleeffectpr.com

SOURCE: PHASTAR



View source version on accesswire.com:
https://www.accesswire.com/665168/ACDM-Honors-PHASTAR-with-Award-for-Innovation-in-the-Management-of-Clinical-Trial-Data

© 2021 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.